GREAT SCIENCE. GREAT MEDICINE.
CREATING BREAKTHROUGH TREATMENTS.
HGS is working to create and develop novel therapies that can extend and improve the quality of life. That is our mission and our passion.
Three Products in Late-Stage Development
We now have three promising products in late-stage development, moving toward commercialization. Phase 3 clinical trials are ongoing for Albuferon® in patients with hepatitis C and LymphoStat-B® in patients with lupus. We are developing both of these products in collaboration with world leaders in the pharmaceutical industry. Also in late-stage development is ABthrax®, which offers a new way to address the threat of inhalation anthrax and is being developed under a contract with the U.S. Government.
High-Potential Mid-Stage Pipeline
Right behind these late-stage products is an emerging, high-potential mid-stage pipeline, led by our TRAIL receptor antibodies for cancer – and including a number of products to which we have substantial financial rights in the GlaxoSmithKline clinical pipeline.
We are committed to improving the lives of patients – and to achieving commercial success and sustainable growth well into the future.